Companies / Nitinotes Surgical

Medical device company profile

Nitinotes Surgical

Israeli device company developing and commercializing EndoZip, an automated endoscopic suturing system for sleeve gastroplasty.

Medical Device Manufacturer and DeveloperGastroenterology & Digestive HealthGastroenterology

Headquarters🇮🇱Caesarea, Israel

Founded2014

Commercial statusCommercially availableCE-marked EndoZip system with European commercial use; investigational in the United States.

Employees11–50 ^[6]LinkedIn company-size range · Checked 2026-11-04

Estimated revenueNot confirmed

Disclosed fundingUS$9.3 million ^[4]SAFE financing closed December 2024, led by MTIP with Techwald and Elron participation.

Official websitenitinotesurgical.com ↗

Company overview

Nitinotes Surgical is an Israeli medical device company based in Caesarea and led by CEO Lloyd Diamond. Founded in 2014, it develops EndoZip, an automated suturing system for endoscopic sleeve gastroplasty, a minimally invasive obesity procedure performed through an endoscope.

EndoZip is designed to place a continuous suture pattern that reduces stomach volume without abdominal incisions. The system combines a suturing device with its delivery and control components, with the goal of making endoscopic gastroplasty more reproducible across operators.

The company announced CE marking in November 2025 and subsequently reported commercial procedures in Spain and France in 2026. In the United States, EndoZip remains investigational and is being evaluated in the EASE randomized clinical trial.

^{[1][2][3][4][5][6]}

Leadership

6 people

Lloyd DiamondChief Executive Officer ^[2]

Raz Bar-OnChief Technology Officer & Chief Global Support ^[2]

Offer NonhoffGeneral Manager, Israel & Chief Financial Officer ^[2]

Hagit EphrathVice President, Clinical, Regulatory Affairs & Quality Assurance ^[2]

Tal YeredVice President, R&D & Engineering ^[2]

Ishay ZighelnicVice President, Supply Chain ^[2]

Products & regulatory status How does MedTechIndex get this information?

Summary

Nitinotes announced CE marking for EndoZip on November 6, 2025. The company subsequently reported European commercial procedures in Spain in April 2026 and France in June 2026. European commercial use does not establish U.S. marketing authorization. ^[5][3]

In the United States, EndoZip is investigational. The EASE trial evaluates EndoZip against endoscopic sleeve gastroplasty using Apollo ESG/OverStitch; trial participation should not be read as FDA marketing clearance. ^[1][2]

Regulatory snapshot How to read this snapshot

U.S. FDA

—
510(k) clearances: —
De Novo grants: —
PMA approvals: —
Recall events

Latest recorded source review: 2026-11-04.

Scope: selected product families.

Commercial portfolio snapshot

Documented commercial product families.

Automated endoscopic suturing system

EndoZip ↗

Automated suturing system designed for endoscopic sleeve gastroplasty. It places a continuous suture pattern to reduce stomach volume through an oral endoscopic procedure. ^[2]

CE-marked · U.S. investigational